Get the Stockscreener App
28.75
1.66%
0.47
After Hours:
28.75
Dianthus Therapeutics Inc stock is traded at $28.75, with a volume of 87,453.
It is up +1.66% in the last 24 hours and up +2.68% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$28.28
Open:
$28.34
24h Volume:
87,453
Relative Volume:
0.47
Market Cap:
$844.28M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-51.44M
1W Performance:
+3.60%
1M Performance:
+2.68%
6M Performance:
+11.43%
1Y Performance:
+139.58%
1-Day Range:
$28.14
$29.19
1-Week Range:
$27.41
$29.19
52-Week Range:
$6.58
$33.77
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
857-201-2700
Address
300 TECHNOLOGY SQUARE, CAMBRIDGE
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - The Manila Times
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - GlobeNewswire Inc.
Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
SG Americas Securities LLC Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5%Should You Buy? - MarketBeat
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - The Manila Times
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4%Here's What Happened - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $45.13 Consensus Target Price from Brokerages - MarketBeat
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.5% – Still a Buy? - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 4.5%Should You Buy? - MarketBeat
Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.7%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Marshall Wace LLP Sells 4,731 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity - MSN
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity (NASDAQ:DNTH) - Seeking Alpha
Oppenheimer Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88 - Defense World
Renaissance Technologies LLC Lowers Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
American Century Companies Inc. Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Fred Alger Management LLC Has $163,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Rating Reiterated by HC Wainwright - MarketBeat
Expert Ratings For Dianthus Therapeutics - Benzinga
Point72 Asia Singapore Pte. Ltd. Acquires 29,159 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asia Singapore Pte. Ltd. Has $1.02 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 40,831 Shares of Stock - Defense World
Dirk Kersten Sells 79,411 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - Defense World
Logos Global Management LP Sells 1,465,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 3% - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Holdings Boosted by Great Point Partners LLC - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Great Point Partners LLC Boosts Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Rhumbline Advisers Acquires Shares of 32,138 Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dropbox CEO Andrew Houston sells shares worth over $87,000 - Investing.com
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.2% - MarketBeat
How does Dianthus Therapeutics Inc (DNTH) change from a tortoise to a hare? - SETE News
Dyne Therapeutics’ (DYN) “Overweight” Rating Reaffirmed at Piper Sandler - Defense World
Incyte Insiders Sold US$4.8m Of Shares Suggesting Hesitancy - Simply Wall St
Victory Capital Management Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.5% - Defense World
31,047 Shares in Incyte Co. (NASDAQ:INCY) Purchased by XTX Topco Ltd - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.5% Higher - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.3% - Defense World
WINTON GROUP Ltd Buys Shares of 10,238 Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - Kilgore News Herald
Dyne Therapeutics director sells over $161k in company stock - Investing.com India
Dyne Therapeutics Inc (DYN) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):